Statin induced myopathy

BMJ

Volumn 337, Issue 7679, 2008, Pages 1159-1162

  Sathasivam, Sivakumar ^a   Lecky, Bryan ^a  

^a WALTON CENTRE FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA TOCOPHEROL; AMIODARONE; ANTIFUNGAL AGENT; ATORVASTATIN; CALCIUM CHANNEL BLOCKING AGENT; CERIVASTATIN; CREATINE KINASE; CYCLOSPORIN; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MACROLIDE; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; PROTEINASE INHIBITOR; PYRROLE DERIVATIVE; ROSUVASTATIN; SIMVASTATIN; UBIDECARENONE; WARFARIN;

ANAMNESIS; CHOLESTEROL SYNTHESIS; CLINICAL FEATURE; CLINICAL TRIAL; CRANBERRY JUICE; CREATINE KINASE BLOOD LEVEL; DRUG ALCOHOL INTERACTION; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; ELECTROMYOGRAPHY; FOOD DRUG INTERACTION; GRAPEFRUIT JUICE; HUMAN; HYDROPHILICITY; HYPERCHOLESTEROLEMIA; LIPOPHILICITY; MONOTHERAPY; MUSCLE BIOPSY; MUSCLE INJURY; MUSCLE WEAKNESS; MYALGIA; MYOPATHY; MYOSITIS; PATIENT MONITORING; PHYSICAL EXAMINATION; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; TREATMENT DURATION;

BIOPSY; CHOLESTEROL; CREATINE KINASE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MUSCULAR DISEASES; RISK FACTORS;

EID: 56749130484     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.a2286     Document Type: Review

References (29)

1. Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol 2006;97(suppl 8A):52-60C.
2. Bays H. Statin safety: an overview and assessment of the data - 2005. Am J Cardiol 2006;97(suppl 8A):6-26C.
3. Bruckert E, Hayem G, Dejager S, Yau C, Bégaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients-the PRIMO study. Cardiovasc Drugs Ther 2005;19:403-14.
4. Scott RS, Lintott CJ, Wilson MJ. Simvastatin and side effects. New Zealand Med J 1991;104:493-5.
5. Gaist D, Rodríguez LA, Huerta C, Hallas J, Sindrup SH. Lipid-lowering drugs and the risk of myopathy: a population-based follow-up study. Epidemiology 2001;12:565-9.
6. Graham DJ, Staffa JA, Shatin D, Andrade SE, Schech SD, La Grenade L, et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 2004;292:2585-90.
7. Hansen KE, Hildebrand JP, Ferguson EE, Stein JH. Outcomes in 45 patients with statin-associated myopathy. Arch Intern Med 2005;165:2671-6.
8. Westwood FR, Bigley A, Randall K, Marsden AM, Scott RC. Statin-induced muscle necrosis in the rat: distribution, development, and fibre selectivity. Toxicol Pathol 2005;33:246-57.
9. Baker SK. Molecular clues into the pathogenesis of statin mediated muscle toxicity. Muscle Nerve 2005;31:572-80.
10. Päivä H, Thelen KM, Van Coster R, Smet J, De Paepe B, Mattila KM, et al. High-dose statins and skeletal muscle metabolism in humans: a randomized controlled trial. Clin Pharmacol Ther 2005;78:60-8.
11. Laaksonen R, Jokelainen K, Sahi T, Tikkanen MJ, Himberg JJ. Decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short-term simvastatin treatment in humans. Clin Pharmacol Ther 1995;57:62-6.
12. Dirks AJ, Jones KM. Statin-induced apoptosis and skeletal myopathy. Am Physiol Cell Physiol 2006;291:1208-12.
13. Thompson PD, Clarkson PM, Rosenson RS. An assessment of statin safety by muscle experts. Am J Cardiol 2006;97(suppl):69-76C.
14. Pasternak RC, Smith SC Jr, Bairey-Merz CM, Grundy SM, Cleeman JI, Lenfant C, et al. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Stroke 2002;33:2337-41.
15. Davidson MH, Robinson JG. Safety of aggressive lipid management. J Am Coll Cardiol 2007;49:1753-62.
16. Vladutiu GD, Simmons Z, Isackson PJ, Tarnopolsky M, Peltier WL, Barboi AC, et al. Genetic risk factors associated with lipid-lowering drug-induced myopathies. Muscle Nerve 2006;34:153-62.
17. Thompson PD, Zmuda JM, Domalik LJ, Zimet RJ, Staggers J, Guyton JR. Lovastatin increases exercise-induced skeletal muscle injury. Metabolism 1997;46:1206-10.
18. Rosenson RS. Current overview of statin-induced myopathy. Am J Med 2004;116:408-16.
19. Keogh A, Macdonald P, Kaan A, Aboyoun C, Spratt P, Mundy J. Efficacy and safety of pravastatin vs simvastatin after cardiac transplantation. J Heart Lung Transplant 2000;19:529-37.
20. Harper CR, Jacobson TA. The broad spectrum of statin myopathy: from myalgia to rhabdomyolysis. Curr Opin Lipidol 2007;18:401-8.
21. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;260:7-22.
22. Meltzer HY, Holy PA. Black-white differences in serum creatine phosphokinase (CPK) activity. Clin Chim Acta 1974;54:215-24.
23. Rowland LP, Willner, J, DiMauro S, Miranda A. Approaches to the membrane theory of Duchenne muscular dystrophy. In: Angelini C, Danieli GA, Fontanari D, eds. Muscular dystrophy - advances and new trends. Amsterdam: Excerpta Medica, 1980:3-13.
24. Phillips PS, Haas RH, Bannykh S, Hathaway S, Gray ML, Kimura BJ, at al. Statin-associated myopathy with normal creatine kinase. Ann Intern Med 2002;137:581-5.
25. Tsivgoulis G, Spengos K, Karandreas N, Panas M, Kladi A, Manta P. Presymptomatic neuromuscular disorders disclosed following statin treatment. Arch Intern Med 2006;166:1519-24.
26. Radcliffe KA, Campbell WW. Statin myopathy. Curr Neurol Neurosci Rep 2008;8:66-72.
27. Draeger A, Monastyrskaya K, Mohaupt M, Hoppeler H, Savolainen H, Allemann C, et al. Statin therapy induces ultrastructural damage in skeletal muscle in patients without myalgia. J Pathol 2006;210:94-102.
28. Baker SK, Samjoo IA. A neuromuscular approach to statin-related myotoxicity. Can J Neurol Sci 2008;35:8-21.
29. Kelly P, Vaso S, Gelato M, McNurlan M, Lawson W. Coenzyme Q10 improves myopathic pain in statin treated patients [abstract]. J Am Coll Cardiol 2005;45(3 Suppl A):3A.